Mylan/3M launch new asthma inhaler; Another abuse-deterrent opioid being developed;

> Mylan ($MYL) announced the launch of the first bioequivalent alternative to GlaxoSmithKline's ($GSK) Seretide Evohaler in the United Kingdom, dubbed Sirdupla. The pressurized metered-dose inhaler to treat asthma will be manufactured by 3M Drug Delivery Systems. More

> Egalet said its investigational opioid passed tests of abuse deterrence. It demonstrated high resistance to crushing and grinding with 11 household tools, and heating the tablet did not alter its resistance to physical manipulation attempts, the company says. More

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.